Table 2.

Integrin inhibitors in clinical development as anticancer agents.

Antibodies	Other names	Target integrin	Comments on highest phase reached	Company	References
LM609	Vitaxin, MEDI-552	αVβ3	Currently in Phase II	Scripps Research Institute	Brooks et al. 1994; Gutheil et al. 2000,McNeel et al. 2005
CNTO95		αVβ3, αVβ5	Currently in phase I	Centocor. Medarex	Trikha et al. 2004,Mullamitha et al. 2007
Ha31/8		α1β1			Senger et al. 2002
17E6		αVβ3		Merck	Mitjans et al. 1995, 2000
Ha1/29		α2β1			Senger et al. 2002
NKI-SAM-1, JBS5		α5β1			Francis et al. 2002
M200	Volociximab Eos-200-4	α5β1	Currently in phase II	Protein design Labs	Protein Design Labs, www.pdl.com
Peptides
SCH 221153					Kumar et al. 2001
EMD 121974	Cilengitide	αVβ5	Currently in phase II	Merck KGaA, EMD Pharmaceuticals, National cancer Institute	Taga et al. 2002
ST1646		αVβ3			Belvisi et al. 2005
angiocidin		α2β1			Sabherwal et al. 2006
18F-Galacto-RGD					Haubner et al. 2004, 2001
Nonpeptidic
SJ749		α5β1			Marinelli et al. 2005; Maglott et al. 2006
E7820		α2 subunit	Phase I	Eisai Medical Research
S36578-2		αVβ3, αVβ5			Maubant et al. 2006
S-247		αVβ3, αVβ5			Reinmuth et al. 2003; Harms et al. 2004